Ratio Therapeutics announced today that it closed a $70 million Series C financing to support its radiopharmaceutical development and manufacturing. Existing investors Duquesne Family Office and Bristol Myers Squibb participated. New investors Catalio Capital Management, Eli Lilly and Wasatch Group joined as well. Boston-based Ratio plans to use the proceeds to fund its next phase…

Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience’s advanced pharmaceutical manufacturing operations in Ohio. Now, Resilience’s production in that region…

Consider a common scenario: a pharmaceutical manufacturing plant has identified the equipment most critical to the success of its processes and has begun tracking overall equipment effectiveness (OEE) for those assets. Management has set an ambitious OEE metric of 95% for those critical machines, and operators and technicians are collaborating closely to make sure they…

BeOne Medicines (Nasdaq:ONC) today announced the investment of $300 million to expand its U.S. manufacturing base. The expansion comes at the company’s flagship clinical and commercial-stage manufacturing and R&D center in Hopewell, New Jersey. It brings BeOne’s total U.S. manufacturing investment to more than $1 billion. BeOne said its latest expansion increases its production capacity…

A Fujifilm Biotechnologies’ commercial-scale cell culture manufacturing facility has been selected for the FDA’s PreCheck Pilot Program, the company announced. The CDMO’s Holly Springs, North Carolina, facility was selected as one of seven participants in the program designed to strengthen United States pharmaceutical manufacturing capabilities and accelerate patient access to critical medicines. “We are honored…

Otsuka ICU Medical today announced plans to invest more than $500 million to expand its U.S. IV solutions manufacturing in Texas. The companies (Otsuka Pharmaceutical Factory and ICU Medical), which launched this joint venture last year, plan to deliver a new facility and significant upgrades to its existing operations in Austin, Texas. They expect the…

Evonik announced today that it plans to invest $100 million to expand its pharmaceutical manufacturing capabilities in the U.S. The Essen, Germany-based company is investing in its Tippecanoe Labs site in Lafayette, Indiana, which houses one of the world’s largest facilities for the production of active pharmaceutical ingredients (APIs). Over the next five years, the…

Codis announced today that it agreed to acquire an oral solid dose (OSD) development and manufacturing plant from Catalent. Acquiring the Nottingham, UK-based facility will add OSD development and small-scale manufacturing capabilities to Codis’ offerings, enabling it to offer a single partner path for integrated spray dry solutions. It can now provide development through clinical…

Besins Healthcare announced today that it acquired UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company. UniD specializes in long-acting drug-delivery technologies, bringing decades of expertise to Besins, which delivers a range of hormone therapies. The company works with advanced polymer technology for complex long-acting delivery systems, including implants and vaginal rings. The companies expect…

Shoko announced today that it completed work on a manufacturing plant for its new pharmaceutical excipient, Viscomedi. The facility saw its full-scale commercial production commence in February 2026. Excipients are the inactive, non-drug substances formulated alongside an active pharmaceutical ingredient (API). South Korea-based Hannong Chemicals has been developing a partially neutralized polyacrylate product for pharmaceutical…